LEASE AGREEMENTLease Agreement • March 22nd, 2013 • Epizyme, Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT is made as of this 15th day of June, 2012, between ARE-TECH SQUARE, LLC, a Delaware limited liability company (“Landlord”), and EPIZYME, INC., a Delaware corporation (“Tenant”).
Epizyme, Inc. Nonstatutory Stock Option Agreement Granted Under 2008 Stock Incentive PlanNonstatutory Stock Option Agreement • March 22nd, 2013 • Epizyme, Inc. • Pharmaceutical preparations
COLLABORATION AND LICENSE AGREEMENT among CELGENE INTERNATIONAL SÀRL, CELGENE CORPORATION and EPIZYME, INC.Collaboration and License Agreement • March 22nd, 2013 • Epizyme, Inc. • Pharmaceutical preparations • New York
This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of the 2nd day of April, 2012 (the “Effective Date”) among Epizyme, Inc., a Delaware corporation having its principal place of business at 325 Vassar Street Suite 2B, Cambridge, Massachusetts 02139, U.S.A. (“EPIZYME”), Celgene International Sàrl, having its principal place of business at Route de Perreux 1, 2017 Boudry, Switzerland (“CELGENE”), and, solely for the purposes of Section 13.21, Celgene Corporation, a Delaware corporation having its principal place of business at 86 Morris Avenue, Summit, New Jersey 07901 (“PARENT”). EPIZYME and CELGENE are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
COMPANION DIAGNOSTICS AGREEMENT BETWEEN EPIZYME, INC. and EISAI CO., LTD. on the one side AND ROCHE MOLECULAR SYSTEMS, INC. on the other sideCompanion Diagnostics Agreement • March 22nd, 2013 • Epizyme, Inc. • Pharmaceutical preparations • Delaware
This Companion Diagnostics Agreement (“Agreement”) is entered into and made effective this 18th day of December 2012 (the “Effective Date”) by and between Epizyme, Inc., having a place of business at 325 Vassar Street, Cambridge, Massachusetts 02139, U.S.A. (“Epizyme”) and Eisai Co., Ltd., having a place of business at Koishikawa 4-6-10, Bunkyo-ku, Tokyo 112-8088, Japan (individually, “Eisai” and collectively with Epizyme, “Pharmaceutical Partners”) on the one side and Roche Molecular Systems, Inc., having a place of business at 4300 Hacienda Drive, Pleasanton, California 94588, U.S.A. (“RMS”) on the other side.
Amendment to Collaboration and License AgreementCollaboration and License Agreement • March 22nd, 2013 • Epizyme, Inc. • Pharmaceutical preparations
This Amendment (this “Amendment”) to the Collaboration and License Agreement dated as of April 1, 2011 (the “Agreement”), by and between Epizyme, Inc., a Delaware corporation (“EPIZYME”), and Eisai Co., Ltd., a Japan corporation (“EISAI”) is effective as of the 31st day of July, 2012 (the “Amendment Effective Date”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
LICENSE AGREEMENTLicense Agreement • March 22nd, 2013 • Epizyme, Inc. • Pharmaceutical preparations • North Carolina
The milestones set forth in clauses (a) through (e) above shall be payable only once upon achievement of such milestone by LICENSEE, its AFFILIATES’ and/or LICENSEE’s or its AFFILIATES’ sublicensees, regardless of the number of COMPANY PRODUCTS and/or LICENSED PRODUCTS developed or commercialized by LICENSEE, its AFFILIATES and/or LICENSEE’s or its AFFILIATES’ sublicensees. Each of the milestones set forth in clauses (f) and (g) shall be payable only with respect to the grant of a sublicense by LICENSEE or its AFFILIATES, as the case may be, to a non-AFFILIATE sublicensee and not with respect to the grant of any further sublicenses by any non-AFFILIATE sublicensee of LICENSEE or of its AFFILIATES.
EPIZYME, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT April 2, 2012Rights Agreement • March 22nd, 2013 • Epizyme, Inc. • Pharmaceutical preparations • Delaware
This Agreement dated as of April 2, 2012 is entered into by and among Epizyme, Inc., a Delaware corporation (the “Company”) and the individuals and entities listed on Exhibit A attached hereto (individually, a “Purchaser” and, collectively, the “Purchasers”).
December 21, 2012Epizyme, Inc. • March 22nd, 2013 • Pharmaceutical preparations
Reference is hereby made to (a) the Collaboration and License Agreement dated as of April 1, 2011 (as amended, the “Collaboration Agreement”), by and between Eisai Co., Ltd. (“Eisai”) and Epizyme, Inc. (“Epizyme”) and (b) the Companion Diagnostics Agreement of even date herewith (the “RMS Agreement”), by and between Epizyme and Eisai, on the one side, and RMS, on the other side.
